Pro: Aprotinin Has a Good Efficacy and Safety Profile Relative to Other Alternatives for Prevention of Bleeding in Cardiac Surgery

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Anesthesia and Analgesia

• Publication date

  2006-12-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1213/01.ane.0000246810.88697.15PMID 17122202
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Effects of aprotinin on plasma coagulation kinetics determined by thrombelastography: role of Factor XI

  2006cited by this paper
• A propensity score case‐control comparison of aprotinin and tranexamic acid in high‐transfusion‐risk cardiac surgery

  2006influential reference
• The risk associated with aprotinin in cardiac surgery.

  2006influential reference
• Total arterial revascularization is safe: multicenter ten-year analysis of 71,470 coronary procedures.

  2006cited by this paper
• The risk of aprotinin: a conflict of evidence.

  2006cited by this paper
• Hormone replacement therapy is safe in women undergoing coronary artery bypass grafting.

  2005cited by this paper
• Does the combination of aprotinin and angiotensin-converting enzyme inhibitor cause renal failure after cardiac surgery?

  2005cited by this paper
• Recombinant factor VIIa for intractable blood loss after cardiac surgery: a propensity score–matched case‐control analysis

  2005influential reference
• Are antifibrinolytic drugs equivalent in reducing blood loss and transfusion in cardiac surgery? A meta-analysis of randomized head-to-head trials

  2005cited by this paper
• Contradicted and initially stronger effects in highly cited clinical research.

  2005cited by this paper
• A multicenter risk index for atrial fibrillation after cardiac surgery.

  2004cited by this paper
• Clinical Inhibition of the Seven-Transmembrane Thrombin Receptor (PAR1) by Intravenous Aprotinin During Cardiothoracic Surgery

  2004cited by this paper
• Effect of aprotinin on clinical outcomes in coronary artery bypass graft surgery: a systematic review and meta-analysis of randomized clinical trials.

  2004influential reference
• Stroke after cardiac surgery: a retrospective analysis of the effect of aprotinin dosing regimens.

  2003cited by this paper
• A randomized trial of aprotinin (Trasylol) on blood loss, blood product requirement, and myocardial injury in total arterial grafting.

  2003cited by this paper
• Aspirin and mortality from coronary bypass surgery.

  2002cited by this paper
• Aprotinin impairs coronary endothelial function and down-regulates endothelial NOS in rat coronary microvascular endothelial cells.

  2002cited by this paper
• Anaphylactic Reactions to Aprotinin Reexposure in Cardiac Surgery: Relation to Antiaprotinin Immunoglobulin G and E Antibodies

  2002cited by this paper
• Aprotinin, Blood Loss, and Renal Dysfunction in Deep Hypothermic Circulatory Arrest

  2001cited by this paper
• Anaphylactic Reactions to Aprotinin Reexposure in Cardiac Surgery: Relation to Antiaprotinin Immunoglobulin G and E Antibodies

  2001cited by this paper
• Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion.

  2001cited by this paper
• The Significance of Preformed Aprotinin-Specific Antibodies in Cardiosurgical Patients

  2000cited by this paper
• Aprotinin does not impair renal haemodynamics and function after cardiac surgery.

  2000cited by this paper
• Aprotinin pretreatment diminishes postischemic myocardial contractile dysfunction in dogs.

  1999cited by this paper
• The impact of renal dysfunction on aprotinin pharmacokinetics during cardiopulmonary bypass.

  1999cited by this paper
• Pharmacokinetics of ε-aminocaproic Acid in Patients Undergoing Aortocoronary Bypass Surgery

  1999cited by this paper
• Pharmacokinetics of epsilon-aminocaproic acid in patients undergoing aortocoronary bypass surgery.

  1999cited by this paper
• Analyses of coronary graft patency after aprotinin use: results from the International Multicenter Aprotinin Graft Patency Experience (IMAGE) trial.

  1998cited by this paper
• Cellular Distribution of Exogenous Aprotinin in the Rat Kidney

  1998cited by this paper
• Prevalence of anaphylactic reactions to aprotinin: analysis of two hundred forty-eight reexposures to aprotinin in heart operations.

  1997cited by this paper
• Aprotinin, cardiac surgery, and factor V Leiden

  1997cited by this paper
• Aprotinin in primary valve replacement and reconstruction: a multicenter, double-blind, placebo-controlled trial.

  1996cited by this paper
• Brief communications Aprotinin and aortic cannula thrombosis

  1996cited by this paper
• Aprotinin and aortic cannula thrombosis.

  1996cited by this paper
• Aprotinin for primary coronary artery bypass grafting: a multicenter trial of three dose regimens.

  1996cited by this paper
• Aprotinin in elective primary bypass surgery. Graft patency and clinical efficacy.

  1995cited by this paper
• Lower cardiac troponin T levels in patients undergoing cardiopulmonary bypass and receiving high-dose aprotinin therapy indicate reduction of perioperative myocardial damage.

  1995cited by this paper
• Influence of aprotinin on early graft thrombosis in patients undergoing myocardial revascularization.

  1994cited by this paper
• Aprotinin for coronary bypass operations: efficacy, safety, and influence on early saphenous vein graft patency. A multicenter, randomized, double-blind, placebo-controlled study.

  1994cited by this paper
• Aprotinin does not decrease early graft patency after coronary artery bypass grafting despite reducing postoperative bleeding and use of donated blood.

  1994cited by this paper
• Is there a phase of hypercoagulability when aprotinin is used in cardiac surgery?

  1994cited by this paper
• Renal tubular protein degradation of radiolabelled aprotinin (Trasylol) in patients with chronic renal failure.

  1993cited by this paper
• Renal dysfunction and intravascular coagulation with aprotinin and hypothermic circulatory arrest.

  1993cited by this paper
• Aprotinin therapy in cardiac operations: a report on use in 41 cardiac centers in the United Kingdom.

  1993cited by this paper
• Aprotinin therapy for reoperative myocardial revascularization: a placebo-controlled study.

  1992influential reference
• Aprotinin decreases release of 6-keto-prostaglandin F1 alpha and increases release of thromboxane B2 in cultured human umbilical vein endothelial cells.

  1992cited by this paper
• Early formation of thrombi on pulmonary artery catheters in cardiac surgical patients receiving high-dose aprotinin.

  1990cited by this paper
• Effects of aprotinin on renal function.

  1984cited by this paper
• Effects of aprotinin on renal function and urinary prostaglandin excretion in conscious rats after acute salt loading.

  1979cited by this paper

• Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion.

  2011cites this paper
• Recent Publications on Medications and Pharmacy

  2009cites this paper
• The blood sparing effect and the safety of aprotinin compared to tranexamic acid in paediatric cardiac surgery.

  2009cites this paper
• Aspirin and Tranexamic Acid for Coronary Artery Surgery (ATACAS) Trial: rationale and design.

  2008cites this paper
• Perioperative renal outcome in cardiac surgical patients with preoperative renal dysfunction: aprotinin versus epsilon aminocaproic acid.

  2008cites this paper
• Full disclosure: not just of conflict, but also of data.

  2008cites this paper
• A Benefit-Risk Review of Systemic Haemostatic Agents

  2008cites this paper
• Perioperative renal protection.

  2008cites this paper
• A Benefit-Risk Review of Systemic Haemostatic Agents

  2008cites this paper
• Not Just of Conflict , but Also of Data THE events of the past 2 yr since the initial controversial

  2008cites this paper
• Cardiac surgery with cardiopulmonary bypass: does aprotinin affect outcome?

  2007cites this paper
• Aprotinin in Cardiac Surgery: A Review of Conventional and Novel Mechanisms of Action

  2007cites this paper
• Pharmacoepidemiology and drug safety

  2007cites this paper
• Aprotinin should not be used routinely in infants and childrenundergoing complex open heart surgery

  2007cites this paper
• Hospital Pharmacy Pulse - Recent Publications on Medications and Pharmacy

  2007cites this paper
• Human factors and the cardiac surgical team: a role for simulation.

  2007cites this paper
• Con: Aprotinin should not be used in cardiac surgery with cardiopulmonary bypass.

  2007cites this paper
• Antifibrinolytic therapy: evidence, bias, confounding (and politics!).

  2007cites this paper
• Recent Publications on Medications and Pharmacy

  2007cites this paper
• Anesthesia for congenital heart disease

  2005influential citation